ATE476992T1 - Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper - Google Patents

Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper

Info

Publication number
ATE476992T1
ATE476992T1 AT04800068T AT04800068T ATE476992T1 AT E476992 T1 ATE476992 T1 AT E476992T1 AT 04800068 T AT04800068 T AT 04800068T AT 04800068 T AT04800068 T AT 04800068T AT E476992 T1 ATE476992 T1 AT E476992T1
Authority
AT
Austria
Prior art keywords
hgf
neutralizing antibodies
antibodies binding
neutralizable epitope
binding
Prior art date
Application number
AT04800068T
Other languages
English (en)
Inventor
Junho Chung
Youngmi Hur
Original Assignee
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct filed Critical Nat Cancer Ct
Application granted granted Critical
Publication of ATE476992T1 publication Critical patent/ATE476992T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04800068T 2003-11-11 2004-11-09 Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper ATE476992T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030079482A KR100556660B1 (ko) 2003-11-11 2003-11-11 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
PCT/KR2004/002888 WO2005044848A1 (en) 2003-11-11 2004-11-09 Neutralizable epitope of hgf and neutralizing antibody binding to the same

Publications (1)

Publication Number Publication Date
ATE476992T1 true ATE476992T1 (de) 2010-08-15

Family

ID=36660022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04800068T ATE476992T1 (de) 2003-11-11 2004-11-09 Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper

Country Status (10)

Country Link
US (2) US7408043B2 (de)
EP (1) EP1694700B1 (de)
JP (1) JP4446393B2 (de)
KR (1) KR100556660B1 (de)
CN (2) CN101434654A (de)
AT (1) ATE476992T1 (de)
AU (1) AU2004287743B2 (de)
DE (1) DE602004028651D1 (de)
ES (1) ES2346887T3 (de)
WO (1) WO2005044848A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) * 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) * 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
EP3135298B1 (de) 2006-01-27 2018-06-06 Keio University Therapeutische mittel für erkrankungen im zusammenhang mit choroidaler neovaskularisation
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2025346B1 (de) 2006-04-07 2016-08-10 Osaka University Mittel zur förderung der muskelregeneration
JP4560582B2 (ja) 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
EP2124952A2 (de) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
WO2011110642A2 (en) 2010-03-10 2011-09-15 Genmab A/S Monoclonal antibodies against c-met
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
EP2402370A1 (de) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Neuartiger Antikörper zur Diagnose und/oder Prognose von Krebs
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
BR122014027420A2 (pt) * 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
CN104321342B (zh) 2012-03-15 2017-12-22 首尔大学校产学协力团 Gremlin‑1抗体
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
BR112016006502A2 (pt) 2013-09-30 2017-09-19 Chugai Pharmaceutical Co Ltd Método para a produção de molécula de ligação de antígeno usando-se fago auxiliar modificado
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2016060297A1 (ko) * 2014-10-16 2016-04-21 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CA3231704A1 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Trem2 antigen binding proteins and uses thereof
WO2023056527A1 (en) * 2021-10-07 2023-04-13 The University Of Queensland Proteinaceous molecules and uses therefor
KR102789265B1 (ko) * 2022-04-14 2025-04-02 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법
KR20230148433A (ko) * 2022-04-14 2023-10-25 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 중화항체의 조합 요법
KR20250058158A (ko) 2023-10-20 2025-04-30 주식회사 셀랩메드 암 치료용 약제학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241574A (zh) * 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体

Also Published As

Publication number Publication date
EP1694700B1 (de) 2010-08-11
JP2007532097A (ja) 2007-11-15
US20090023894A1 (en) 2009-01-22
CN101434654A (zh) 2009-05-20
DE602004028651D1 (de) 2010-09-23
AU2004287743B2 (en) 2008-10-09
WO2005044848A1 (en) 2005-05-19
EP1694700A4 (de) 2007-10-31
US7408043B2 (en) 2008-08-05
EP1694700A1 (de) 2006-08-30
CN100447158C (zh) 2008-12-31
HK1098769A1 (zh) 2007-07-27
US20070036789A1 (en) 2007-02-15
ES2346887T3 (es) 2010-10-21
CN1878790A (zh) 2006-12-13
AU2004287743A1 (en) 2005-05-19
KR100556660B1 (ko) 2006-03-10
JP4446393B2 (ja) 2010-04-07
KR20050045419A (ko) 2005-05-17

Similar Documents

Publication Publication Date Title
DE602004028651D1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
NO2017032I1 (no) bezlotoksumab
NZ782442A (en) Antibodies that bind cd39 and uses thereof
LU92710I2 (fr) Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza)
NZ597767A (en) Antibodies to IL-6 and use thereof
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
ECSP20025198A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
SG166090A1 (en) Il-13 binding agents
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
DE602006013029D1 (de) Anti-egfr-antikörper
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
ATE550353T1 (de) Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
BR112022023117A2 (pt) Constructos de anticorpos de domínio único neutralizantes de sars-cov2
JOP20210279A1 (ar) طرق لعلاج حالات مصابة بالتهاب المفاصل الصدفي
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
IL177825A0 (en) Natural igm antibodies and inhibitors thereof
ATE552266T1 (de) Modifizierte hiv-1-hüllproteine
DE50300486D1 (de) Chromatreduziertes hydraulisches Bindemittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1694700

Country of ref document: EP